Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Short Interest Rises 1,170.7%

Posted by Paula Ricardo on Oct 28th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 367,297 shares, a growth of 1,170.7% from the September 30th total of 28,906 shares. Based on an average daily volume of 1,015,424 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the company’s shares are sold short.

Fresenius SE & Co. Trading Up 0.9%

OTCMKTS:FSNUY traded up $0.12 during trading hours on Wednesday, reaching $12.93. 2,709 shares of the company were exchanged, compared to its average volume of 169,482. Fresenius SE & Co. has a 1-year low of $10.33 and a 1-year high of $33.93. The business has a 50 day moving average of $12.92 and a 200 day moving average of $12.90.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. On average, research analysts anticipate that Fresenius SE & Co. will post 1.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

FSNUY has been the topic of several recent analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company presently has a consensus rating of “Buy”.

View Our Latest Analysis on Fresenius SE & Co.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.